Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease.
Richard P Mills, Donald L Budenz, Paul P Lee...
https://pubmed.ncbi.nlm.nih.gov/16386972/Actively Recruiting
Led by Select Eye Care · Updated on 2025-08-29
60
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating how well Direct Selective Laser Trabeculoplasty DSLT lowers eye pressure in adult non-Caucasian patients with primary open angle glaucoma POAG. The study focuses on comparing eye pressure without glaucoma medications washed out eye pressure before and 6 months after the DSLT procedure. This research aims to better understand the effectiveness of DSLT in lowering intraocular pressure in this patient group. Participants will receive the DSLT treatment using the Belkin Vision Eagle Device on one or both eyes. The study includes follow-up visits at 1 month, 3 months, and 6 months after the procedure to monitor vision and eye pressure. These visits assess the reduction in eye pressure and whether participants need additional glaucoma medications or procedures during the 6 months after treatment. During the study, participants will have their vision and intraocular pressure measured at scheduled visits. Researchers will track the amount of eye pressure reduction, the proportion of eyes achieving significant pressure decrease, and the number of medication-free eyes at 6 months. Safety and the need for any extra glaucoma treatments will also be monitored. The total study duration for each participant is 6 months after the DSLT procedure.
CONDITIONS
Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma
S
Scott E LaBorwit, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Select Eye Care
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | DSLT (Belkin device) | Standard SLT (current guideline‑based care) |
|---|---|---|
| What it is | A novel automated selective laser trabeculoplasty using the Belkin Vision Eagle device applied directly through the cornea to lower intra‑ocular pressure | Established SLT laser therapy for lowering eye pressure in mild to moderate primary open‑angle glaucoma |
| Role in trial | Single investigational treatment administered to all enrolled participants | Not delivered in this trial; included here as external standard of care |
| Primary use | Lowering intra‑ocular pressure in treatment‑naive or washed out POAG patients of Black African descent | Reducing intra‑ocular pressure as a commonly recommended first‑line treatment in mild to moderate POAG |
| How it is given or performed | Delivered using the Belkin Vision Eagle device in a single‑group protocol as defined in trial | Performed as outpatient selective laser applied to drainage angle to improve fluid outflow |
| Evidence status | Efficacy under evaluation; trial will measure IOP reduction at 6 months post‑DSLT | Proven effective; LiGHT trial showed cost‑effective IOP control and quality‑of‑life gains over drops at 3 to 6 years |
| Important risks | Not yet established; safety data pending trial results | Low incidence of adverse events reported in SLT over several years |
| Important limitations | Single‑arm trial without comparator; no long‑term efficacy or safety data yet | Outcomes may differ by population; LiGHT trial mostly included patients outside Black African descent group |
| Patient impact | Not yet known; trial will measure IOP lowering and potential need for additional interventions at 6 months | SLT first‑line use led to sustained medication‑free pressure control, improved quality of life, and lower surgery rates over 6 years |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive Direct Selective Laser Trabeculoplasty (DSLT) treatment using the Belkin Vision Eagle Device.
1 visit (in-person)
Duration - 6 months
Participants are monitored for intraocular pressure reduction and need for secondary interventions after DSLT treatment.
Follow-up visits at 1 month, 3 months, and 6 months post-DSLT
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Richard P Mills, Donald L Budenz, Paul P Lee...
https://pubmed.ncbi.nlm.nih.gov/16386972/Michael A Kass, Dale K Heuer, Eve J Higginbotham...
https://pubmed.ncbi.nlm.nih.gov/12049574/Nathan Congdon, Augusto Azuara-Blanco, Yoram Solberg...
https://pubmed.ncbi.nlm.nih.gov/34433548/Lyne Racette, M Roy Wilson, Linda M Zangwill...
https://pubmed.ncbi.nlm.nih.gov/12745004/Mordechai Goldenfeld, Michael Belkin, Masha Dobkin-Bekman...
https://pubmed.ncbi.nlm.nih.gov/34003939/Gus Gazzard, Evgenia Konstantakopoulou, David Garway-Heath...
https://pubmed.ncbi.nlm.nih.gov/36122660/Remo Susanna, Roberto M Vessani
https://pubmed.ncbi.nlm.nih.gov/19834563/Bret A Hughes, Jason Bacharach, E Randy Craven...
https://pubmed.ncbi.nlm.nih.gov/16148589/Select Eye Care
Lead Sponsor